A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity
- 12 November 2010
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 25 (1) , 66-74
Abstract
Asparaginase is an important component for treatment of childhood acute lymphoblastic leukemia (ALL). The basis for interindividual differences in asparaginase sensitivity remains unclear. To comprehensively identify genetic variants important in the cytotoxicity of asparaginase, we used a genome-wide association approach using the HapMap lymphoblastoid cell lines (87 CEU trio members) and 54 primary ALL leukemic blast samples at diagnosis. Asparaginase sensitivity was assessed as the drug concentration necessary to inhibit 50% of growth (inhibitory concentration (IC)50). In CEU lines, we tested 2 390 203 single-nucleotide polymorphism (SNP) genotypes at the individual SNP (PP50. The aspartate metabolism pathway was the most overrepresented among 199 pathways evaluated (P=8.1 × 10−3), with primary involvement of adenylosuccinate lyase and aspartyl-tRNA synthetase genes. We validated that SNPs in the aspartate metabolism pathway were also associated with asparaginase sensitivity in primary ALL leukemic blast samples (P=5.5 × 10−5). Our genome-wide interrogation of CEU cell lines and primary ALL blasts revealed that inherited genomic interindividual variation in a plausible candidate pathway can contribute to asparaginase sensitivity.Keywords
This publication has 60 references indexed in Scilit:
- Pharmacogenomic Discovery Using Cell-Based ModelsPharmacological Reviews, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemiaBlood, 2009
- Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicityBlood, 2009
- Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Identification of Genetic Variants Contributing to Cisplatin-Induced Cytotoxicity by Use of a Genomewide ApproachThe American Journal of Human Genetics, 2007
- Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginaseJournal of Clinical Investigation, 2007
- Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell linesBritish Journal of Cancer, 2006
- Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyBlood, 2006
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000